80 related articles for article (PubMed ID: 11089231)
21. Escherichia coli cells resistant to the DNA gyrase inhibitor, ciprofloxacin, overproduce a 60 kD protein homologous to GroEL.
Hallett P; Mehlert A; Maxwell A
Mol Microbiol; 1990 Mar; 4(3):345-53. PubMed ID: 1972534
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of differential activities of ofloxacin enantiomers.
Morrissey I; Hoshino K; Sato K; Yoshida A; Hayakawa I; Bures MG; Shen LL
Antimicrob Agents Chemother; 1996 Aug; 40(8):1775-84. PubMed ID: 8843280
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
Onodera Y; Tanaka M; Sato K
J Antimicrob Chemother; 2001 Apr; 47(4):447-50. PubMed ID: 11266418
[TBL] [Abstract][Full Text] [Related]
24. Transient relaxation of plasmid DNA in Escherichia coli by fluoroquinolones.
Matsuo M; Ohtsuka Y; Kataoka K; Mizushima T; Sekimizu K
J Pharm Pharmacol; 1996 Sep; 48(9):985-7. PubMed ID: 8910869
[TBL] [Abstract][Full Text] [Related]
25. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
Zhao X; Xu C; Domagala J; Drlica K
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
[TBL] [Abstract][Full Text] [Related]
26. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.
Bazile S; Moreau N; Bouzard D; Essiz M
Antimicrob Agents Chemother; 1992 Dec; 36(12):2622-7. PubMed ID: 1336340
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
Schulte A; Heisig P
J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
[No Abstract] [Full Text] [Related]
28. Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628.
Lewin CS
J Med Microbiol; 1992 May; 36(5):353-7. PubMed ID: 1316970
[TBL] [Abstract][Full Text] [Related]
29. Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group.
Erwin ME; Jones RN
J Clin Microbiol; 1999 Jan; 37(1):279-80. PubMed ID: 9988595
[No Abstract] [Full Text] [Related]
30. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
García-Calvo G; Parra A; Ponte C; Soriano F; Giménez MJ; Aguilar L
Int J Antimicrob Agents; 2002 Dec; 20(6):477-80. PubMed ID: 12458147
[No Abstract] [Full Text] [Related]
31. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
McCullough JE; Muller MT; Howells AJ; Maxwell A; O'Sullivan J; Summerill RS; Parker WL; Wells JS; Bonner DP; Fernandes PB
J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
[No Abstract] [Full Text] [Related]
32. DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.
Strahilevitz J; Truong-Bolduc QC; Hooper DC
Antimicrob Agents Chemother; 2005 Dec; 49(12):5051-7. PubMed ID: 16304172
[TBL] [Abstract][Full Text] [Related]
33. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.
Heddle JG; Blance SJ; Zamble DB; Hollfelder F; Miller DA; Wentzell LM; Walsh CT; Maxwell A
J Mol Biol; 2001 Apr; 307(5):1223-34. PubMed ID: 11292337
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
Denis A; Moreau NJ
J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860
[TBL] [Abstract][Full Text] [Related]
35. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
36. Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 1997 Apr; 39(4):549-50. PubMed ID: 9145831
[No Abstract] [Full Text] [Related]
37. DNA gyrase and DNA supercoiling.
Gellert M; Mizuuchi K; O'Dea MH; Ohmori H; Tomizawa J
Cold Spring Harb Symp Quant Biol; 1979; 43 Pt 1():35-40. PubMed ID: 225107
[No Abstract] [Full Text] [Related]
38. Identification of DNA topoisomerases involved in immediate and transient DNA relaxation induced by heat shock in Escherichia coli.
Ogata Y; Mizushima T; Kataoka K; Miki T; Sekimizu K
Mol Gen Genet; 1994 Sep; 244(5):451-5. PubMed ID: 8078472
[TBL] [Abstract][Full Text] [Related]
39. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
40. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
